{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T17:25:52Z","timestamp":1649179552763},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Das Nationale Referenzzentrum (NRZ) f\u00fcr Hepatitis-B-Viren (HBV) und Hepatitis-D-Viren (HDV) befindet sich seit seiner Gr\u00fcndung und Berufung im Jahr 2011 am Institut f\u00fcr Medizinische Virologie der Justus-Liebig-Universit\u00e4t Gie\u00dfen (JLU). In diesem Beitrag werden die T\u00e4tigkeitsbereiche des NRZ und die damit verbundenen Erfahrungen beschrieben.<\/jats:p><jats:p>Das NRZ bietet eine umfassende Beratungst\u00e4tigkeit zu allen diagnostischen und klinischen Aspekten der akuten und chronischen Infektion mit HBV und HDV f\u00fcr den \u00d6ffentlichen Gesundheitsdienst (\u00d6GD), diagnostische Laboratorien, Kliniken, Forschungsinstitute und niedergelassene \u00c4rzte. Unklare diagnostische Befunde k\u00f6nnen mit der am NRZ etablierten HBV\/HDV-Spezialdiagnostik unter Verwendung von aktuellen molekularbiologischen, biochemischen und genetischen Untersuchungsmethoden analysiert, interpretiert und epidemiologische Zusammenh\u00e4nge aufgekl\u00e4rt werden. Das NRZ kann dabei auf eine umfangreiche Stammsammlung von vielen gut charakterisierten und klonierten HBV\/HDV-Isolaten zur\u00fcckgreifen, die eine vergleichende Analyse und Bewertung von antiviralen Resistenzmutationen und Immunescape-Varianten zul\u00e4sst. Das NRZ initiiert und begleitet mit seinen nationalen und internationalen Partnerinstitutionen unter anderem Ringversuche zur Diagnostik der HBV-Resistenz, einschlie\u00dflich Immunescape, zur Entwicklung und Validierung von internationalen Standards der Weltgesundheitsorganisation (WHO) und zur Optimierung der quantitativen HDV-Genombestimmung. Das NRZ beteiligt sich aktiv an aktuellen Empfehlungen und Leitlinien zu HBV und HDV sowie an Empfehlungen von medizinischen Fachgesellschaften. Es weist mit Beitr\u00e4gen in Form von nationalen und internationalen Vortr\u00e4gen sowie mit Originalarbeiten und Kommentaren in nationalen und internationalen Journalen auf aktuelle HBV\/HDV-relevante Aspekte hin.<\/jats:p>","DOI":"10.1007\/s00103-021-03479-7","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T09:02:57Z","timestamp":1641891777000},"page":"220-227","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["10\u00a0Jahre Nationales Referenzzentrum f\u00fcr Hepatitis-B-Viren und Hepatitis-D-Viren in Gie\u00dfen: T\u00e4tigkeiten und Erfahrungen"],"prefix":"10.1007","volume":"65","author":[{"given":"Dieter","family":"Glebe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Goldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Giese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yassine","family":"Hida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram H.","family":"Gerlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ziebuhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Slanina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian G.","family":"Sch\u00fcttler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"3479_CR1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijmm.2015.08.007","volume":"305","author":"S Beermann","year":"2015","unstructured":"Beermann\u00a0S, Allerberger\u00a0F, Wirtz\u00a0A, Burger\u00a0R, Hamouda\u00a0O (2015) Public health microbiology in Germany: 20\u00a0years of national reference centers and consultant laboratories. Int J Med Microbiol 305:595\u2013600","journal-title":"Int J Med Microbiol"},{"key":"3479_CR2","unstructured":"Robert Koch Institut (2021) Gesamtliste der Nationalen Referenzzentren und Konsiliarlabore. https:\/\/www.rki.de\/DE\/Content\/Infekt\/NRZ\/nrz_uebersicht_gesamt_node.html;jsessionid=4881EECD5DD77736F8FBB9807A03DB4A.internet122. Zugegriffen: 11.2021"},{"key":"3479_CR3","volume-title":"Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact","author":"WHO","year":"2021","unstructured":"WHO (2021) Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact. World Health Organization, Geneva"},{"key":"3479_CR4","first-page":"3","volume":"29","author":"S Burdi","year":"2021","unstructured":"Burdi\u00a0S, Harder\u00a0T, Ullrich\u00a0A, Krings\u00a0A, Sandford\u00a0M, Dudareva\u00a0S (2021) Virushepatitis B und D im Jahr 2020. Epidemiol Bull 29:3\u201321","journal-title":"Epidemiol Bull"},{"key":"3479_CR5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3389\/fpubh.2020.00424","volume":"8","author":"I Sperle","year":"2020","unstructured":"Sperle\u00a0I, Steffen\u00a0G, Leendertz\u00a0SA et\u00a0al (2020) Prevalence of hepatitis B, C, and D in Germany: results from a\u00a0scoping review. Front Public Health 8:424","journal-title":"Front Public Health"},{"key":"3479_CR6","volume-title":"MIQ: Mikrobiologisch-infektiologische Qualit\u00e4tsstandards","author":"CG Sch\u00fcttler","year":"2020","unstructured":"Sch\u00fcttler\u00a0CG, Slanina\u00a0H, G\u00e4rtner\u00a0B, Huzly\u00a0D, Modrow\u00a0S (2020) MiQ 25 Diagnostik viraler Hepatitiden. In: Podbielski\u00a0A, Abele-Horn\u00a0M, Becker\u00a0K, Kniehl\u00a0E, R\u00fcssmann\u00a0H, Schubert\u00a0S, Zimmermann\u00a0S (Hrsg) MIQ: Mikrobiologisch-infektiologische Qualit\u00e4tsstandards. Elsevier, M\u00fcnchen"},{"key":"3479_CR7","unstructured":"Robert Koch Institut (2016) Allgemeiner Aufgabenkatalog f\u00fcr Nationale Referenzzentren (NRZ). https:\/\/www.rki.de\/DE\/Content\/Infekt\/NRZ\/Aufgabenkatalog_NRZ\/Aufgabenkatalog_NRZ_node.html. Zugegriffen: 11.2021"},{"key":"3479_CR8","doi-asserted-by":"crossref","first-page":"104973","DOI":"10.1016\/j.antiviral.2020.104973","volume":"186","author":"D Glebe","year":"2021","unstructured":"Glebe\u00a0D, Goldmann\u00a0N, Lauber\u00a0C, Seitz\u00a0S (2021) HBV evolution and genetic variability: impact on prevention, treatment and development of antivirals. Antiviral Res 186:104973","journal-title":"Antiviral Res"},{"key":"3479_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","volume":"57","author":"A Kramvis","year":"2014","unstructured":"Kramvis\u00a0A (2014) Genotypes and genetic variability of hepatitis B virus. Intervirology 57:141\u2013150","journal-title":"Intervirology"},{"key":"3479_CR10","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","volume":"67","author":"N Rajoriya","year":"2017","unstructured":"Rajoriya\u00a0N, Combet\u00a0C, Zoulim\u00a0F, Janssen\u00a0HLA (2017) How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J\u00a0Hepatol 67:1281\u20131297","journal-title":"J Hepatol"},{"key":"3479_CR11","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.meegid.2011.04.017","volume":"11","author":"NM Araujo","year":"2011","unstructured":"Araujo\u00a0NM, Waizbort\u00a0R, Kay\u00a0A (2011) Hepatitis B virus infection from an evolutionary point of view: how viral, host, and environmental factors shape genotypes and subgenotypes. Infect Genet Evol 11:1199\u20131207","journal-title":"Infect Genet Evol"},{"key":"3479_CR12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","volume":"101","author":"HJ Flink","year":"2006","unstructured":"Flink\u00a0HJ, van Zonneveld\u00a0M, Hansen\u00a0BE et al (2006) Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101:297\u2013303","journal-title":"Am J Gastroenterol"},{"key":"3479_CR13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2009.12.014","volume":"52","author":"S Raimondi","year":"2010","unstructured":"Raimondi\u00a0S, Maisonneuve\u00a0P, Bruno\u00a0S, Mondelli\u00a0MU (2010) Is response to antiviral treatment influenced by hepatitis B virus genotype? J\u00a0Hepatol 52:441\u2013449","journal-title":"J Hepatol"},{"key":"3479_CR14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41575-020-0296-6","volume":"17","author":"PA Revill","year":"2020","unstructured":"Revill\u00a0PA, Tu\u00a0T, Netter\u00a0HJ, Yuen\u00a0LKW, Locarnini\u00a0SA, Littlejohn\u00a0M (2020) The evolution and clinical impact of hepatitis B virus genome diversity. Nat Rev Gastroenterol Hepatol 17:618\u2013634","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3479_CR15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijmm.2015.08.016","volume":"305","author":"PL Seiz","year":"2015","unstructured":"Seiz\u00a0PL, Slanina\u00a0H, Ziebuhr\u00a0J, Gerlich\u00a0WH, Glebe\u00a0D, Sch\u00fcttler\u00a0CG (2015) Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany suggest a\u00a0major role of hepatitis B e antigen expression in disease severity and progression. Int J Med Microbiol 305:663\u2013672","journal-title":"Int J Med Microbiol"},{"issue":"10","key":"3479_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3390\/genes9100495","volume":"9","author":"S Velkov","year":"2018","unstructured":"Velkov\u00a0S, Ott\u00a0JJ, Protzer\u00a0U, Michler\u00a0T (2018) The global hepatitis B virus genotype distribution approximated from available genotyping data. Genes 9(10):495. https:\/\/doi.org\/10.3390\/genes9100495","journal-title":"Genes"},{"key":"3479_CR17","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000360950","volume":"57","author":"D Glebe","year":"2014","unstructured":"Glebe\u00a0D, Geipel\u00a0A (2014) Selected phenotypic assays used to evaluate antiviral resistance and viral fitness of hepatitis B virus and its variants. Intervirology 57:225\u2013231","journal-title":"Intervirology"},{"key":"3479_CR18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jhep.2013.11.024","volume":"60","author":"T Berg","year":"2014","unstructured":"Berg\u00a0T, Zoulim\u00a0F, Moeller\u00a0B et al (2014) Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J\u00a0Hepatol 60:715\u2013722","journal-title":"J Hepatol"},{"key":"3479_CR19","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/gutjnl-2014-308435","volume":"65","author":"YS Lim","year":"2016","unstructured":"Lim\u00a0YS, Yoo\u00a0BC, Byun\u00a0KS et al (2016) Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a\u00a0randomised trial. Gut 65:1042\u20131051","journal-title":"Gut"},{"key":"3479_CR20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3851\/IMP2928","volume":"20","author":"A Geipel","year":"2015","unstructured":"Geipel\u00a0A, Seiz\u00a0PL, Niekamp\u00a0H et\u00a0al (2015) Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine. Antivir Ther 20:779\u2013787","journal-title":"Antivir Ther"},{"key":"3479_CR21","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMc1400292","volume":"370","author":"A Geipel","year":"2014","unstructured":"Geipel\u00a0A, Glebe\u00a0D, Will\u00a0H, Gerlich\u00a0WH (2014) Hepatitis B virus rtI233V mutation and resistance to adefovir. N\u00a0Engl J Med 370:1667\u20131668","journal-title":"N Engl J Med"},{"key":"3479_CR22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1055\/a-1498-2512","volume":"59","author":"M Cornberg","year":"2021","unstructured":"Cornberg\u00a0M, Sandmann\u00a0L, Protzer\u00a0U et al (2021) S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion \u2013 (AWMF-Register-Nr.\u00a0021\u201311). Z\u00a0Gastroenterol 59:691\u2013776","journal-title":"Z Gastroenterol"},{"key":"3479_CR23","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0264-410X(97)00080-7","volume":"15","author":"R del Canho","year":"1997","unstructured":"del Canho\u00a0R, Grosheide\u00a0PM, Mazel\u00a0JA et al (1997) Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982\u20131992: protective efficacy and long-term immunogenicity. Vaccine 15:1624\u20131630","journal-title":"Vaccine"},{"key":"3479_CR24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.28302","volume":"63","author":"RS Brown Jr.","year":"2016","unstructured":"Brown\u00a0RS Jr., Mcmahon\u00a0BJ, Lok\u00a0AS et al (2016) Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology 63:319\u2013333","journal-title":"Hepatology"},{"key":"3479_CR25","volume-title":"Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy","author":"WHO","year":"2020","unstructured":"WHO (2020) Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. World Health Organization, Geneva"},{"key":"3479_CR26","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00103-019-03084-9","volume":"63","author":"D Glebe","year":"2020","unstructured":"Glebe\u00a0D, van Boemmel\u00a0F, Dudareva\u00a0S et al (2020) Pr\u00e4vention der nosokomialen \u00dcbertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen T\u00e4tige: Empfehlungen der Deutschen Vereinigung zur Bek\u00e4mpfung der Viruskrankheiten (DVV) e.\u202fV. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63:218\u2013225","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"3479_CR27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok\u00a0AS, McMahon\u00a0BJ, Brown\u00a0RS Jr. et al (2016) Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63:284\u2013306","journal-title":"Hepatology"},{"key":"3479_CR28","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.24318","volume":"53","author":"C Hongthanakorn","year":"2011","unstructured":"Hongthanakorn\u00a0C, Chotiyaputta\u00a0W, Oberhelman\u00a0K et\u00a0al (2011) Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 53:1854\u20131863","journal-title":"Hepatology"},{"key":"3479_CR29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/apt.15864","volume":"52","author":"M Cornberg","year":"2020","unstructured":"Cornberg\u00a0M, Glebe\u00a0D (2020) Editorial: which factors influence HBsAg levels in HBV-infected patients? Aliment Pharmacol Ther 52:547\u2013548","journal-title":"Aliment Pharmacol Ther"},{"key":"3479_CR30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jcv.2016.05.009","volume":"82","author":"PL Seiz","year":"2016","unstructured":"Seiz\u00a0PL, Mohr\u00a0C, Wilkinson\u00a0DE et\u00a0al (2016) Characterization of the 3rd international standard for hepatitis B virus surface antigen (HBsAg). J\u00a0Clin Virol 82:166\u2013172","journal-title":"J Clin Virol"},{"key":"3479_CR31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jcv.2016.06.003","volume":"82","author":"DE Wilkinson","year":"2016","unstructured":"Wilkinson\u00a0DE, Seiz\u00a0PL, Sch\u00fcttler\u00a0CG et\u00a0al (2016) International collaborative study on the 3rd WHO international standard for hepatitis B surface antigen. J\u00a0Clin Virol 82:173\u2013180","journal-title":"J Clin Virol"},{"key":"3479_CR32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale\u00a0AJ, Kreuels\u00a0B, Henrion\u00a0MYR et al (2020) The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J\u00a0Hepatol 73:523\u2013532","journal-title":"J Hepatol"},{"key":"3479_CR33","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.29574","volume":"66","author":"F Le Gal","year":"2017","unstructured":"Le Gal\u00a0F, Brichler\u00a0S, Drugan\u00a0T et\u00a0al (2017) Genetic diversity and worldwide distribution of the deltavirus genus: a study of 2,152 clinical strains. Hepatology 66:1826\u20131841","journal-title":"Hepatology"},{"key":"3479_CR34","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","volume":"73","author":"D Roulot","year":"2020","unstructured":"Roulot\u00a0D, Brichler\u00a0S, Layese\u00a0R et\u00a0al (2020) Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J\u00a0Hepatol 73:1046\u20131062","journal-title":"J Hepatol"},{"key":"3479_CR35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cgh.2013.01.025","volume":"11","author":"S Brichler","year":"2013","unstructured":"Brichler\u00a0S, Le Gal\u00a0F, Butt\u00a0A, Chevret\u00a0S, Gordien\u00a0E (2013) Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia. Clin Gastroenterol Hepatol 11:734\u2013740","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3479_CR36","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1002\/hep.28772","volume":"64","author":"F Le Gal","year":"2016","unstructured":"Le Gal\u00a0F, Brichler\u00a0S, Sahli\u00a0R, Chevret\u00a0S, Gordien\u00a0E (2016) First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology 64:1483\u20131494","journal-title":"Hepatology"},{"key":"3479_CR37","unstructured":"Chudy M, Hanschmann KM, Bozdayi M, Kre\u00df J, N\u00fcbling CM (2013) Collaborative study to establish a\u00a0world health organization international standard for hepatitis D virus RNA for nucleic acid amplification technique (NAT)-based assays. http:\/\/www.who.int\/biologicals\/expert_committee\/BS_2227_HDV_RNA.pdf. Zugegriffen: 11.2021"},{"key":"3479_CR38","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/jvh.13385","volume":"28","author":"LS Pfl\u00fcger","year":"2021","unstructured":"Pfl\u00fcger\u00a0LS, Schulze Zur Wiesch\u00a0J, Polywka\u00a0S, L\u00fctgehetmann\u00a0M (2021) Hepatitis delta virus propagation enabled by hepatitis C virus-scientifically intriguing, but is it relevant to clinical practice? J\u00a0Viral Hepat 28:213\u2013216","journal-title":"J Viral Hepat"},{"key":"3479_CR39","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/s41467-019-10117-z","volume":"10","author":"J Perez-Vargas","year":"2019","unstructured":"Perez-Vargas\u00a0J, Amirache\u00a0F, Boson\u00a0B et al (2019) Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. Nat Commun 10:2098","journal-title":"Nat Commun"},{"key":"3479_CR40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.31453","volume":"73","author":"I Chemin","year":"2021","unstructured":"Chemin\u00a0I, Pujol\u00a0FH, Scholtes\u00a0C et\u00a0al (2021) Preliminary evidence for hepatitis delta virus exposure in patients who are apparently not infected with hepatitis B virus. Hepatology 73:861\u2013864","journal-title":"Hepatology"},{"key":"3479_CR41","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/infdis\/jiaa517","volume":"223","author":"P Cappy","year":"2021","unstructured":"Cappy\u00a0P, Lucas\u00a0Q, Kankarafou\u00a0N, Sureau\u00a0C, Laperche\u00a0S (2021) No evidence of hepatitis C virus (HCV)-assisted hepatitis D virus propagation in a\u00a0large cohort of HCV-positive blood donors. J\u00a0Infect Dis 223:1376\u20131380","journal-title":"J Infect Dis"},{"issue":"9","key":"3479_CR42","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.3390\/v13091799","volume":"13","author":"I Roggenbach","year":"2021","unstructured":"Roggenbach\u00a0I, Chi\u00a0X, Lempp\u00a0FA et al (2021) HDV seroprevalence in HBsAg-positive patients in China occurs in hotspots and is not associated with HCV mono-infection. Viruses 13(9):1799","journal-title":"Viruses"},{"key":"3479_CR43","doi-asserted-by":"crossref","first-page":"vez021","DOI":"10.1093\/ve\/vez021","volume":"5","author":"WS Chang","year":"2019","unstructured":"Chang\u00a0WS, Pettersson\u00a0JH, Le Lay\u00a0C et al (2019) Novel hepatitis D\u2011like agents in vertebrates and invertebrates. Virus Evol 5:vez21","journal-title":"Virus Evol"},{"key":"3479_CR44","doi-asserted-by":"crossref","first-page":"17977","DOI":"10.1073\/pnas.2006750117","volume":"117","author":"S Paraskevopoulou","year":"2020","unstructured":"Paraskevopoulou\u00a0S, Pirzer\u00a0F, Goldmann\u00a0N et\u00a0al (2020) Mammalian deltavirus without hepadnavirus coinfection in the neotropical rodent proechimys semispinosus. Proc Natl Acad Sci U S\u00a0A 117:17977\u201317983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3479_CR45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00103-020-03260-2","volume":"64","author":"R Zimmermann","year":"2021","unstructured":"Zimmermann\u00a0R, Kulper-Schiek\u00a0W, Steffen\u00a0G et al (2021) How to assess the elimination of viral hepatitis B, C, and D in Germany? Outcomes of an interdisciplinary workshop. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 64:77\u201390","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"3479_CR46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill\u00a0PA, Chisari\u00a0FV, Block\u00a0JM et\u00a0al (2019) A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 4:545\u2013558","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3479_CR47","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","volume":"71","author":"G Raimondo","year":"2019","unstructured":"Raimondo\u00a0G, Locarnini\u00a0S, Pollicino\u00a0T et\u00a0al (2019) Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J\u00a0Hepatol 71:397\u2013408","journal-title":"J Hepatol"},{"key":"3479_CR48","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2014.05.018","volume":"61","author":"A K\u00f6nig","year":"2014","unstructured":"K\u00f6nig\u00a0A, D\u00f6ring\u00a0B, Mohr\u00a0C, Geipel\u00a0A, Geyer\u00a0J, Glebe\u00a0D (2014) Kinetics of the bile acid transporter and hepatitis B virus receptor Na+\/taurocholate cotransporting polypeptide (NTCP) in hepatocytes. J\u00a0Hepatol 61:867\u2013875","journal-title":"J Hepatol"},{"key":"3479_CR49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.virusres.2015.10.024","volume":"211","author":"I Kucinskaite-Kodze","year":"2016","unstructured":"Kucinskaite-Kodze\u00a0I, Pleckaityte\u00a0M, Bremer\u00a0CM et al (2016) New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen. Virus Res 211:209\u2013221","journal-title":"Virus Res"},{"key":"3479_CR50","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2018.01.029","volume":"68","author":"BF de Carvalho Dominguez Souza","year":"2018","unstructured":"de Carvalho Dominguez Souza\u00a0BF, K\u00f6nig\u00a0A, Rasche\u00a0A et\u00a0al (2018) A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses. J\u00a0Hepatol 68:1114\u20131122","journal-title":"J Hepatol"},{"key":"3479_CR51","doi-asserted-by":"crossref","first-page":"16151","DOI":"10.1073\/pnas.1308049110","volume":"110","author":"JF Drexler","year":"2013","unstructured":"Drexler\u00a0JF, Geipel\u00a0A, K\u00f6nig\u00a0A et\u00a0al (2013) Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci U S\u00a0A 110:16151\u201316156","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"3479_CR52","doi-asserted-by":"publisher","first-page":"e2013982118","DOI":"10.1073\/pnas.2013982118","volume":"118","author":"A Rasche","year":"2021","unstructured":"Rasche\u00a0A, Lehmann\u00a0F, Goldmann\u00a0N et\u00a0al (2021) A hepatitis B virus causes chronic infections in equids worldwide. Proc Natl Acad Sci U S\u00a0A 118(13):e2013982118. https:\/\/doi.org\/10.1073\/pnas.2013982118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3479_CR53","doi-asserted-by":"crossref","first-page":"17007","DOI":"10.1073\/pnas.1908072116","volume":"116","author":"A Rasche","year":"2019","unstructured":"Rasche\u00a0A, Lehmann\u00a0F, K\u00f6nig\u00a0A et\u00a0al (2019) Highly diversified shrew hepatitis B viruses corroborate ancient origins and divergent infection patterns of mammalian hepadnaviruses. Proc Natl Acad Sci U S\u00a0A 116:17007\u201317012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3479_CR54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1099\/jgv.0.001415","volume":"101","author":"L Magnius","year":"2020","unstructured":"Magnius\u00a0L, Mason\u00a0WS, Taylor\u00a0J et\u00a0al (2020) ICTV virus taxonomy profile: hepadnaviridae. J\u00a0Gen Virol 101:571\u2013572","journal-title":"J Gen Virol"},{"key":"3479_CR55","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2020.08.039","volume":"74","author":"M Pfefferkorn","year":"2021","unstructured":"Pfefferkorn\u00a0M, Schott\u00a0T, B\u00f6hm\u00a0S et al (2021) Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J\u00a0Hepatol 74:283\u2013292","journal-title":"J Hepatol"},{"key":"3479_CR56","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","volume":"67","author":"M Pfefferkorn","year":"2018","unstructured":"Pfefferkorn\u00a0M, B\u00f6hm\u00a0S, Schott\u00a0T et\u00a0al (2018) Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a\u00a0novel tool for the identification of inactive HBV carriers. Gut 67:2045\u20132053","journal-title":"Gut"},{"key":"3479_CR57","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/liv.14298","volume":"40","author":"F Rinker","year":"2020","unstructured":"Rinker\u00a0F, Bremer\u00a0CM, Schr\u00f6der\u00a0K et al (2020) Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. Liver Int 40:324\u2013332","journal-title":"Liver Int"},{"key":"3479_CR58","doi-asserted-by":"crossref","first-page":"606.e1","DOI":"10.1016\/j.cmi.2015.02.010","volume":"21","author":"B Maasoumy","year":"2015","unstructured":"Maasoumy\u00a0B, Wiegand\u00a0SB, Jaroszewicz\u00a0J et al (2015) Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a\u00a0large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 21:606.e1\u2013606.e10","journal-title":"Clin Microbiol Infect"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03479-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-021-03479-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03479-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T07:05:11Z","timestamp":1643871911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-021-03479-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3479"],"URL":"https:\/\/doi.org\/10.1007\/s00103-021-03479-7","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"assertion":[{"value":"24 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Lehmann, N.\u00a0Goldmann, A.\u00a0Giese, Y.\u00a0Hida, W.H.\u00a0Gerlich, J.\u00a0Ziebuhr, H.\u00a0Slanina und C.G.\u00a0Sch\u00fcttler geben an, dass kein Interessenkonflikt besteht. D.\u00a0Glebe war Berater f\u00fcr Fresenius Medical Care und Viravaxx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}